News
INVA
15.24
-0.33%
-0.05
Weekly Report: what happened at INVA last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at INVA last week (0311-0315)?
Weekly Report · 03/18 09:12
Weekly Report: what happened at INVA last week (0304-0308)?
Weekly Report · 03/11 09:12
Armata enters $35M credit agreement with Innoviva
Healthcare Armata enters $35M credit agreement with Innoviva. Proceeds will be used to advance the lead therapeutic phage candidates. Armata Pharmaceuticals is the largest shareholder of Innoviva, Inc. (NASDAQ:INVA) Armata shares rose 1% in pre-market trading.
Seeking Alpha · 03/04 21:10
Press Release: Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva. Proceeds to be used to advance rigorously designed clinical trials of high purity phage-based therapeutic candidates. Armata is a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant bacterial infections.
Dow Jones · 03/04 21:01
5 Value Stocks In The Healthcare Sector
A value stock traditionally has a lower price when compared to companies in the same industry. This indicates that the company may be undervalued. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. The following stocks are considered to be notable value stocks in the healthcare sector.
Benzinga · 03/04 14:44
Weekly Report: what happened at INVA last week (0226-0301)?
Weekly Report · 03/04 09:12
Press Release: Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results. Core royalty platform on track; received GSK royalties of $69.6 million for fourth quarter. Achieved net product revenues of $19.7 million for the fourth quarter of 2023 representing 35% year on year growth. Approval and launch of first pathogen targeted antibacterial XACDURO(R) for treatment of Acinetobacter infections in 2023. Positive Phase 3 data for oral drug zoliflodacin for the treatment of gonorrhea.
Dow Jones · 03/01 00:06
Press Release: Innoviva Reports Fourth Quarter -3-
Investments Capitalized fees and other fees are more than $1.2 billion. The total number of assets and liabilities is more than 1.6 billion. The total value of the assets is $8.5 billion. There are $560,000,000 in cash, but more than half of that is in the form of convertible notes.
Dow Jones · 03/01 00:06
Innoviva Inc reports results for the quarter ended in December - Earnings Summary
Innoviva Inc reports quarterly adjusted earnings of 76 cents per share for the quarter ended in December. Revenue rose 30.4% to $85.84 million from a year ago. The company's shares had fallen by 4.3% this quarter. Wall Street's median 12-month price target for Innoviva is $15.
Reuters · 02/29 22:24
*Innoviva 4Q EPS 76c >INVA
Dow Jones · 02/29 21:05
Weekly Report: what happened at INVA last week (0219-0223)?
Weekly Report · 02/26 09:13
Weekly Report: what happened at INVA last week (0212-0216)?
Weekly Report · 02/19 09:14
Dominate the Market With 3 Biotech Stocks
Investors could consider buying fundamentally strong biotech stocks Innoviva (INVA), Foghorn Therapeutics (FHTX), and Vertex Pharmaceuticals (VRTX) The biotech industry’s growth prospects look promising due to the use of advanced technologies in drug development. The growing popularity of personalized medicine, an aging population, and expanding healthcare needs are boosting the long-term growth prospects of the biotech industry. Innoviva, Inc. Uses advanced technologies to develop targeted treatments for various diseases.
Barchart · 02/16 08:56
Weekly Report: what happened at INVA last week (0205-0209)?
Weekly Report · 02/12 09:13
Here's Why Innoviva (NASDAQ:INVA) Can Manage Its Debt Responsibly
Innoviva, Inc. Has US$445.7m of debt on its balance sheet. The company's EBIT fell 58% in the last 12 months. Debt is a tool to help a company grow, but it can also be a problem for a company. We look at debt levels to see if the debt is making the company risky. Innoviva has a moderate net debt to EBITDA ratio of 1.9. This suggests the company is managing its debt well. However, the company has 5 warning signs it has a high debt burden.
Simply Wall St · 02/05 10:15
Weekly Report: what happened at INVA last week (0129-0202)?
Weekly Report · 02/05 09:14
Weekly Report: what happened at INVA last week (0122-0126)?
Weekly Report · 01/29 09:13
Innoviva: Statement of changes in beneficial ownership of securities
Press release · 01/23 04:05
Innoviva: [Amend]Statement of acquisition of beneficial ownership by individuals
Press release · 01/22 20:05
More
Webull provides a variety of real-time INVA stock news. You can receive the latest news about Innoviva through multiple platforms. This information may help you make smarter investment decisions.
About INVA
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA. The Company's products include GIAPREZA and XERAVA. GIAPREZA (angiotensin II) injection is approved by the United States Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAV (eravacycline) for injection is approved by the United States FDA and Singapore Health Sciences Authority (HSA) as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI).